VistaGen Therapeutics Inc (VTGN)

[StockLogistics]

Gotta ramp up tomorrow and Friday and continue to turn the bollinger bands on the one month and six month charts to trend higher

[FORDGT]

In August, 2022 the (VTGN) VistaGen Therapeutics, Inc. SqueezeTrigger Price was $0.15. If you had purchased VTGN, the trade would have gained 2.45% as of today's price of $0.16. If you had traded 10,000 shares, you would currently have a gain of $38.00.

[StockLogistics]

Monday and Tuesday will be important to keep the upper bollinger band above the 100 SMA and 50 SMA on the 6 month chart, needs to rise in a major way to avoid that.

[Odiwon]

This is looking good

[Steph70]

Wow .15! I’m in for a ride

[Porterhouse10]

Support lost, bummer

[HeilHiden]

I averaged down costs Pennies to do so

[ksviking12]

For those inquisitive minds, the company learns from each clinical trial. They have a potentially game-changing treatment that is being tested at every level. Each time they test, fail or succeed, they learn more. Their pipeline is robust. Let’s see how this plays out. The full readout will be very interesting.

[ksviking12]

How can anyone say there will be confidence of lack thereof? We haven’t seen the readout. What we do know, is the company would have to basically go bankrupt to see a pos at $0.01. So let’s stop pretending that’s a possibility.

[StockLogistics]

That’s what they said on the 20th, how can investors have confidence in any of these drugs after the failure in the short term, the next report isn’t until later in ‘22, the rumor of that report is diminished in the near term imo, thus lower

[StockLogistics]

VTGN .15 buy?

[StockLogistics]

This was posted as stock analysis on 7/20/22 (follow the prose):

““2 “Strong Buy” Penny Stocks That Could Go Boom

Michael Marcus (Author)

Between the Fed’s aggressive policy tightening to rein in inflation and deteriorating economic data, volatility has become a seemingly ever-present facet of the stock market. While the current economic landscape has spurred fear among investors, others view market volatility as a unique buying opportunity.

Opportunity is the key word – and sometimes the hardest thing for investors to see. To find names that can deliver solid returns and now come with a bargain price tag, investors will often turn to penny stocks, or those trading for less than $5 per share.

Sure, there could be a very good reason these tickers are so affordable, but should there be even minor share price appreciation, massive percentage gains could materialize, along with hefty profits for investors.

So, how are investors supposed to determine which names have what it takes to make a comeback? Follow the pros.

Using TipRanks’ database, we were able to pinpoint two promising penny stocks, according to Wall Street analysts. Both tickers boast a Strong Buy consensus rating and could climb over 300% higher in the year ahead.

VistaGen Therapeutics (VTGN)

We’ll start with VistaGen, a biopharmaceutical research company with a focus on disorders of the central nervous system. The company’s leading programs are new treatments for anxiety and depression, serious conditions with large potential patient bases. According to recent governmental health authority data, some 264 million people worldwide suffer from depression-related disorders, 19.4 million US adults have experienced at least one major depressive episode, and some 25 million people suffer from social anxiety disorders (SADs) in the US alone. This is the population that VistaGen aims to help.

The company has three main drug candidate programs, each one with a different pharmacological mode of action and target condition. The leading candidate is PH94B, a new treatment for social anxiety disorder. The drug, administered by nasal spray, is currently undergoing the PALISADE clinical trials. PALISADE-1, a phase 3 study that followed 208 patients across 15 clinical sites in the US, is focused on the use of PH94B as an acute treatment for rapid onset anxiety in adults. VistaGen announced last month that the study is now complete, and topline results will be available this year. PALISADE-2, another phase 3 trial of identical size and scope, in still underway, with topline results expected in late 2022. PH94B has been granted ‘fast track’ status by the FDA.

The other two clinical programs, PH10 and AV-101, are less advanced. PH10 is under development as a treatment for depression, and is also administered as a nasal spray. An exploratory phase 2a trial showed promise, and VistaGen is assembling an Investigational New Drug application for the FDA, to gain approval for a phase 2b clinical trial of PH10 in the treatment of major depressive disorder.

AV-101, a drug candidate being studies as a treatment for neurological disorders, is the subject of a phase 1b drug-drug interaction study, in combination with probenecid. AV-101 is an orally dosed product, and VistaGen is considering further trials as a combination therapy with probenecid.

Currently going for only $0.82 apiece, at least one member of the Street believes that now is the right time to snap up shares.

Baird’s Brian Skorney has reviewed VistaGen’s current position and sees plenty to be optimistic about. The key point, in his view, is the soon-to-be-released data from PALISADE-1, which should give investors reason to buy in.

“We continue to view the inbound top-line readout, expected no later than mid-August, as a crucial catalyst for the PH94B opportunity in SAD. We continue to think the existing data support the expectation that the study will hit on its primary endpoint, offering a favorable risk/reward at the current valuation,” Skorney opined.

“We continue to see substantial upside potential with PH94B in SAD and other forms of anxiety disorders, and believe current valuation of VTGN underestimates the clinical proof of concept and the commercial potential,” the analyst added.

To this end, Skorney rates VTGN an Outperform (i.e. Buy), and his price target, at $9, suggests just how much he expects that outperformance: up to 997% in the coming year. (To watch Skorney’s track record, click here)

Other analysts are on the same page. With 2 additional Buy ratings, the word on the Street is that VTGN is a Strong Buy. On top of this, the average price target is $7, suggesting robust growth of ~754%. (See VTGN stock forecast on TipRanks)”

https://www.tipranks.com/news/article/2-strong-buy-penny-stocks-that-could-go-boom-3?utm_source=advfn.com&utm_medium=referral

Tip Ranks Last….-85%.

[StockLogistics]

Never posted on RGBP and I follow zero accounts

[HeilHiden]

You’ve been following me around since RGBP crashed

[HeilHiden]

Leave

[ksviking12]

Not true at all. They have a full pipeline of drugs and are trading lowered than their cash value. It could go lower, but it’s not going to $0.01 and the downside risk from here is minimal.

[StockLogistics]

It didn’t move off the .15 the entire day so maybe it will go lower, need something other than the current story to get willing buyers at higher prices, time could be a good thing because it gives them time to fix the drugs so they actually work, could see .01 without consistent company communication (weekly at minimum) midterm/long term, investors will be constantly asking “prove that you didn’t give up completely”

The transaction date of this 10% insider purchase says 7/30/22 at .74:

https://ih.advfn.com/stock-market/NASDAQ/vistagen-therapeutics-VTGN/stock-news/88605870/statement-of-changes-in-beneficial-ownership-4

[Rafa636]

This isn't weakness, this is a debacle!!

[HeilHiden]

BUY ON WEAKNESS SELL ON STRENGTH.

[vein]

I guess it’s game over here

[whosjohngalt]

one way or the other

we are pretty close now, been a long road.

best
who

[whosjohngalt]

eh

picked up another 1k this week, small fry me but building a decent collection here. After all these years time is short here now with vista, one way or the other.

Looks like sub dollar next week perhaps, will add again.

best all
who

[whosjohngalt]

think so yup

should be a good year, and nice to see a little wake up this week. Was a long winter.

best to you
who

[Rafa636]

2022 should be a great year for us....Here is today's PR..


https://us.etrade.com/e/t/invest/wsoddirect?wsod_page=%2Fv1%2Fnews%2Fmarketnews%2Fmarketnews.asp%3FdocKey%3D1-SN20220210016164-016164%26DMSourceID%3DDJNF%26Source%3DPMZN%26DisplayName%3DGlobeNewswire%26docDate%3D2022-02-10%252021%253A20%253A00%26headline%3DVistaGen%2520Therapeutics%2520Reports%2520Third%2520Quarter%2520Financial%2520Results%2520and%2520Provides%2520Corporate%2520Update

[whosjohngalt]

all is well here

seems a waiting game, 2nd half 2022 should we continue down this road without a bump. so far so good, good luck to us.

best
who

[TurdBlossom]

Nice finish today

[whosjohngalt]

good start

to the new year. Happy new year.

best
who

[Johnny_C]

Nice volume!!! 1 of the Phase 3 trials completed. Might take a couple months for data

[Johnny_C]

Short positions are closing and institutional holdings now up to 74 percent

[Johnny_C]

Institutions buying heavy, institutional ownership jumped from 53% to 75% in the last few weeks.

[whosjohngalt]

yep

agree on 2022, just sleeping on this company. Tempting to pick a few more up sub 2 bucks but haven't pulled the trigger yet. See how far it drifts.

best
who

[Johnny_C]

Board seems quite lately. I think 2022 will be VTGN's big breakout

[whosjohngalt]

all good

200 mil o/s
90 plus mil in the bank
no testing issues to date

things are starting to move much faster now, by mid to late 2022 this little snowball should really start barreling down the slope barring any test issues.

https://finance.yahoo.com/news/vistagen-therapeutics-reports-fiscal-2022-212000925.html

best,
who

[Johnny_C]

Yup, like several other holdings patience hopefully pats off big

[whosjohngalt]

all

is good.

best
who

[Johnny_C]

Nice volume at close

[whosjohngalt]

agree

figure mid next year just sleeping on this, no hiccups like you said that's what matters. It takes alot of years sometimes to get to the beginning.

best
who

[Johnny_C]

I think the wait will be less than 6 months now, if results are announced in Q1 2022.

Fingers crossed the results are at least duplicative of Phase 2. Some estimates have up 10 to 15 percent of US adults suffer from depression or anxiety.

A fast safe nasal effective anxiety drug would be a game changer for sure

[whosjohngalt]

like a circus

this board, everyone calm down.

[whosjohngalt]

VistaGen is a no brainer

https://finance.yahoo.com/news/vistagen-therapeutics-reports-preclinical-mechanism-120000504.html

[whosjohngalt]

some

pretty big hitter buying into the bell to close out the week, wonder if something is up for next week. Not a typical pattern.

best
who

[whosjohngalt]

seems a bunch

of day flippers today, not much of a day flip stock vistagen.

top line results mid 2022, we either nail it or we don't. All good so far.

best,
who

[whosjohngalt]

nice update

onward and upward

https://finance.yahoo.com/news/vistagen-therapeutics-further-advances-palisade-100000038.html

[whosjohngalt]

nice to see 3's again

solid support on low volume bodes very well, we move upwards to 5 as 94b phase 3 progresses this year.

best all
who

[whosjohngalt]

would add

as far as other disorders regarding 94B, I think an effective and safe treatment for ptsd would be the one that really gets everyone's attention.

just my opinion

[whosjohngalt]

sure sounds

like top line results this calendar year, on 94B for SAD specifically. Branching off to other disorders for next year if everything continues well. Thinking the other disorders will fall in line pretty quickly if we get through this initial phase 3 safely and effectively.

Never can tell though, all I wanted to hear is things are progressing without any issues; we'll get there.

best regards
who

[Richard2]

Been trading $MNRA options this week, what did I miss? Any timelines given?

[whosjohngalt]

good conference call

everything on track no issues, so far so good

best
who

[Richard2]

Price holding up nicely here

[whosjohngalt]

probably an update

prior to next weeks fireside I would guess.

best